17:57 , Jul 20, 2018 |  BC Week In Review  |  Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to...
18:27 , Apr 5, 2018 |  BC Innovations  |  Emerging Company Profile

Stoking protein production

Stoke Therapeutics Inc. is developing ASOs to boost normal protein expression as disease-modifying therapies for autosomal-dominant diseases that are not amenable to recombinant protein or gene therapies. Co-founders Adrian Krainer and Isabel Aznarez previously discovered cell...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
21:55 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Ovid reports Phase I data for CYP46A1 inhibitor OV935

Ovid Therapeutics Inc. (NASDAQ:OVID) reported data from a pair of Phase I trials in 88 healthy volunteers showing that single ascending doses of up to 1,350 mg and multiple ascending doses of up to 400...
00:07 , Dec 22, 2017 |  BC Innovations  |  Strategy

Ovid spreads its wings

With its first two candidates for rare neurological disorders heading towards clinical proof of concept, Ovid Therapeutics Inc. is looking to capitalize on the experience it has gained to find compounds with differentiated pharmacology that...
00:45 , Jun 24, 2017 |  BioCentury  |  Strategy

Takeda’s modality operandi

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a...
00:00 , May 6, 2017 |  BC Extra  |  Financial News

Ovid dips in first trading day

Ovid Therapeutics Inc. (NASDAQ:OVID) fell $2.75 (18%) to $12.25 in its first day of trading Friday. The company priced its $75 million IPO after market hours on Thursday (see BioCentury Extra, May 4). The company's lead...
23:50 , May 4, 2017 |  BC Extra  |  Financial News

Ovid prices $75M IPO

Neurological disease company Ovid Therapeutics Inc. (NASDAQ:OVID) raised $75 million through the sale of 5 million shares at $15 in an IPO underwritten by Citigroup, Cowen, William Blair and JMP Securities. The price valued the...
19:57 , Apr 11, 2017 |  BC Extra  |  Financial News

Ovid planning $86.3M IPO

Neurologic disease company Ovid Therapeutics Inc. (New York, N.Y.) proposed to raise $86.3 million in an IPO on NASDAQ underwritten by Citigroup, Cowen, William Blair and JMP Securities. On Monday, Ovid said it began a Phase...
22:24 , Jan 20, 2017 |  BioCentury  |  Strategy

Marriage of minds

An unusual deal between Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics Inc. represents both a continuation of the biotech CEO’s long-time approach to portfolio building, and a new way of thinking about external innovation at...